FILANA THERAPEUTICS, INC. (FLNA) stock intrinsic value fair value estimate & owner earnings analysis

Filana Therapeutics (Nasdaq: FLNA) is the company formerly known as Cassava Sciences, which spent much of the last decade developing a drug called simufilam as a treatment for Alzheimer's disease. That program ended in 2024 after Phase 3 studies failed to show benefit, and the wind-down was completed in mid-2025. The company also settled a related SEC matter in 2024, and in February 2026 the Department of Justice closed its inquiry into the company without bringing any charges against it. The company has since renamed itself and redirected its only drug candidate, simufilam, toward a different and much smaller population: children and adults with seizures caused by tuberous sclerosis complex (TSC), a rare genetic condition. The company holds patents on simufilam running into the late 2030s and licensed related research from Yale University in early 2025. This is not a business with sales, profits, or an established product to project forward — it has never generated product revenue and has spent cash every year since at least 2014. That makes a conventional profit-and-growth valuation the wrong tool here. Instead, the shares are best understood today as a claim on the company's cash on hand, minus what it will likely spend before (or unless) its epilepsy program produces something of value, plus whatever a partner or acquirer might pay for that program's potential. As of the most recent quarter, the company held roughly $87 million in cash, against about 48 million shares outstanding — near $1.80 per share in cash alone, close to where the stock itself has traded. Spending has fallen sharply now that the costly Alzheimer's trials and related legal defense costs are behind the company. Our bear case assumes the TSC-epilepsy program encounters a setback or delay, no partner or acquirer steps in over the next couple of years, and the company has to raise more money by issuing shares at a discounted price — diluting existing holders. That case is worth around $0.70 per share. Our base case assumes the company runs a modestly sized study of simufilam in TSC-related epilepsy using its existing cash, without assuming the study succeeds or fails — simply that the company continues operating along its current, leaner spending path. That case comes out to about $1.55 per share, a bit below today's cash-per-share level, reflecting that some of that cash will be spent before any answer arrives. Our bull case assumes the epilepsy program shows enough early promise to attract a licensing partner or acquirer, in which case the shares could be worth meaningfully more than the cash alone, on the order of $4.50 per share, reflecting the value of a first-in-class treatment for an underserved condition with a long patent runway. On this basis, the margin-of-safety price is near $0.95 per share, set so that it is supported by the more cautious outcomes, while the bull case shows meaningful upside if the epilepsy program advances. That price also depends on a clear, dated study plan being disclosed, since that detail is not yet public. One thing we could not fully untangle from the filings: net income and cash spending have moved very differently from each other in some recent years. This appears to reflect non-cash accounting swings tied to the value of warrants the company had outstanding until their 2024 redemption, along with legal and litigation-related charges, rather than the underlying pace of spending on research and operations.